Xilio Therapeutics, Inc. · NASDAQ:XLO
Xilio Therapeutics, Inc. shareholders
As of Sep 30, 2026, 27 institutions reported holding Xilio Therapeutics, Inc., 44.3% of its shares. Largest: Bain Capital Life Sciences Investors, LLC, Orbimed Advisors LLC and Adage Capital Partners Gp, L.L.C. New holders, exits, insiders and big stakes, each with its filing.
| Holder | Shares | % of Xilio Therapeutics, Inc. | Change | Filed |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664K | 9.4% | no change | Nov 16, 2026 |
| Orbimed Advisors LLC | 592K | 8.4% | no change | Nov 16, 2026 |
| Adage Capital Partners Gp, L.L.C. | 465K | 6.6% | +353K | Nov 16, 2026 |
| Frazier Life Sciences Management, L.P. | 423K | 6.0% | no change | Nov 16, 2026 |
| Vanguard | 230K | 3.3% | +28,622 | Nov 13, 2026 |
| Stonepine Capital Management, LLC | 189K | 2.7% | −36,902 | Nov 13, 2026 |
| Sio Capital Management, LLC | 152K | 2.2% | no change | Nov 16, 2026 |
| Merck & Co., Inc. | 106K | 1.5% | no change | Nov 13, 2026 |
| Renaissance Technologies | 63,553 | 0.90% | −600 | Nov 12, 2026 |
| Morgan Stanley | 53,674 | 0.76% | −3,280 | Nov 13, 2026 |